Aptose Reports Results for the First Quarter 2023
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...
United States Tuspetinib Monotherapy Aptose Biosciences Susan Pietropaolo American Society Of Hematology European School Of Haematology
Source: wallstreet-online.de